LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Long noncoding RNA OIP5‐AS1 promotes the stemness of lung cancer cells through enhancing Oct4 mRNA stability

Photo by nci from unsplash

Long noncoding RNA (lncRNA) OIP5‐AS1 was shown to facilitate drug resistance and metastasis in several tumors. As cancer stem cells (CSCs) have been elucidated as the origin of drug resistance… Click to show full abstract

Long noncoding RNA (lncRNA) OIP5‐AS1 was shown to facilitate drug resistance and metastasis in several tumors. As cancer stem cells (CSCs) have been elucidated as the origin of drug resistance and tumor progression, we speculate that lncRNA OIP5‐AS1 holds critical roles in the CSC‐like traits of lung cancer. Here, lncRNA OIP5‐AS1 was found to be highly expressed in lung cancer cell spheres. Following experiments showed that OIP‐AS1 knockdown reduced the CSC‐like traits of lung cancer spheres, while overexpression of OIP‐AS1 conferred the CSC‐like traits in lung cancer cells by performing sphere‐formation analysis, detecting stemness marker expression, and ALDH activity. Mechanistic studies revealed that lncRNA OIP5‐AS1 could increase Oct4 expression by directly interacting with Oct4 mRNA and enhancing Oct4 mRNA stability. Finally, we found that the knockdown of Oct4 could rescue the promoting effects of OIP5‐AS1 overexpression on the CSC‐like traits of lung cancer. These results demonstrate that lncRNA OIP5‐AS1 can confer lung cancer CSC‐like traits by directly interacting with Oct4 mRNA and thus increasing Oct4 mRNA stability and expression.

Keywords: lung cancer; oct4 mrna; oip5 as1; lncrna oip5; cancer

Journal Title: Environmental Toxicology
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.